Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2023 (GLOBE…
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory (R/R) Large B Cell…